FACE-PC: Family-Centered Care for Older Adults With Depression and Chronic Medical Conditions in Primary Care

Depression Clinical Trial

— FACE-PC  

Official title:

FACE-PC: Family-Centered Care for Older Adults With Depression and Chronic Medical Conditions in Primary Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03094871
• Other study ID #: 17-23224
• Status: Completed
• Phase: N/A
• Start date: April 1, 2015
• Est. completion date: December 30, 2020

Study information

• Verified date: November 2021
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comorbid depression and multiple medical conditions in older adults are a serious public health problem. As an important facilitator of health-related activities, families are already involved in various aspects of self-management of chronic disease in older adults. Despite the benefits they provide, informal caregiving activities currently are organized outside the medical system, which potentially creates redundant or misaligned efforts.The purpose of the mentored research is to examine the feasibility and acceptability of the FACE-PC, a theory-driven, multi- component, technology-assisted interdisciplinary team-based care model that systematically involves family in chronic disease management. It aims to optimize the patient and family's collective ability to self-manage chronic disease.

Description:

Comorbid depression and multiple medical conditions in older adults are a serious public health problem. As an important facilitator of health-related activities, families are already involved in various aspects of self-management of chronic disease in older adults. Despite the benefits they provide, informal caregiving activities currently are organized outside the medical system, which potentially creates redundant or misaligned efforts.The purpose of the mentored research is to examine the feasibility and acceptability of the FACE-PC, a theory-driven, multi- component, technology-assisted interdisciplinary team-based care model that systematically involves family in chronic disease management. It aims to optimize the patient and family's collective ability to self-manage chronic disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 30, 2020
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria for Patient:

• 60 years of age or older

• Receives primary care

• PHQ-9 score = 5

• Must have at least one medical condition actively managed at the study site.

Inclusion Criteria for Family:

• Age 18 or older

• Identified as family by the patient

• Has a minimum of twice weekly total of 4 hour face-to face contact with the patient

• Is willing and available to participate in the study;

• Has access to internet.

Exclusion Criteria for Patient:

• Inability to understand screening and assessment questions

• Montreal Cognitive Assessment Scores <18

• Known diagnosis of a severe chronic mental illness such as schizophrenia

• Meeting the criteria for bipolar disorder or schizophrenia in PRIME-MD

• Deemed to be a danger to self or others that may require treatment outside a primary care setting.

Exclusion Criteria for Family:

• Institutionalized at the time of study.

Related Conditions & MeSH terms

• Chronic Medical Conditions
• Depression
• Depressive Disorder
• Disease

Intervention

Behavioral:
• FACE-PC

Locations

Country	Name	City	State
United States	University of California San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Mood assessed with Patient Health Questionnaire	Patient Health Questionnaire	at baseline, 2-months post-intervention, and 5-months follow-up